Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Revenue: ₺744.6 Mil (TTM As of Mar. 2026)


IST:ONCSM Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
80 GF Score
Price ₺250.50
GF Value ₺253.44
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Oncosem Onkolojik Sistemlernayi ve Ticaret AS Revenue?

Oncosem Onkolojik Sistemlernayi ve Ticaret AS IST:ONCSM 80 Revenue is ₺744.6 Mil as of Mar. 2026. GuruFocus rates IST:ONCSM with a GF Score™ of 80/100 and a GF Value™ of ₺253.44 (Fairly Valued). The stock has 4 warning signs investors should review.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS's revenue for the three months ended in Mar. 2026 was ₺239.0 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₺744.6 Mil. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue per Share for the three months ended in Mar. 2026 was ₺10.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₺31.22.

During the past 12 months, the average Revenue per Share Growth Rate of Oncosem Onkolojik Sistemlernayi ve Ticaret AS was 26.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 34.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was 48.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 7 years, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's highest 3-Year average Revenue per Share Growth Rate was 83.00% per year. The lowest was 34.30% per year. And the median was 53.65% per year.


Oncosem Onkolojik Sistemlernayi ve Ticaret AS  (IST:ONCSM) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Oncosem Onkolojik Sistemlernayi ve Ticaret AS Revenue Related Terms


Oncosem Onkolojik Sistemlernayi ve Ticaret AS Revenue Historical Data

* Premium members only.

The historical data trend for Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Revenue Chart

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 127.99 292.94 347.24 490.18 709.08

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.52 164.05 155.84 185.71 239.00

IST:ONCSM vs ABT, SYK, MDT: Revenue Comparison

For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncosem Onkolojik Sistemlernayi ve Ticaret AS Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue distribution charts can be found below:

* The bar in red indicates where Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue falls into.


IST:ONCSM
80GF Score
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS IST:ONCSM
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncosem Onkolojik Sistemlernayi ve Ticaret AS Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺744.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of ₺744.6 Mil mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a Revenue of ₺744.6 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Revenue is ₺744.6 Mil. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue compare to ABT and SYK?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Revenue of ₺744.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Revenue is ₺744.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺253.44, compared to a current price of ₺250.50 — trading 1.2% below its estimated fair value. The current Revenue is ₺744.6 Mil. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current Revenue is ₺744.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?

Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued. The current stock price of ₺250.50 is trading 1.2% below its estimated GF Value™ of ₺253.44. GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.

Key valuation signals for IST:ONCSM:

  • Revenue: ₺744.6 Mil
  • GF Value™: ₺253.44 vs. price of ₺250.50 (1.2% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description

Address Mutlukent Mah. 1988 Cad. No: 12, Cankaya, Ankara, TUR
Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS is specialized in the production of equipment and medical devices used in cancer treatment.
80GF Score

Get the complete analysis for IST:ONCSM

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₺250.50
Price
₺253.44
GF Value